Delivery Order SPE2DR25D3303-SPE2DR26F63G2
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,033.47 to AmerisourceBergen Drug Corp for the supply of Lantus SoloStar 100 Unit/mL 3mL insulin pens. The contract was competitively awarded without set-aside designation under a firm fixed-price arrangement, with performance scheduled for completion by August 18, 2025. AmerisourceBergen will fulfill this order from its corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary...
- The U.S. Department of Defense's Defense Logistics Agency (DLA) Troop Support Medical has awarded a firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, to provide Lantus Solostar 100 unit/ml 3ml insulin pens. The $1,850.53 contract has a performance period through March 12, 2024. AmerisourceBergen Drug Corp holds an indefinite delivery contract (IDC) with DLA Troop Support Medical valued at up to $999,999,999.00 through December...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,310.67 to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL 3mL insulin pens. This non-set-aside, competitively awarded contract operates under a firm fixed-price model with an ultimate completion date of December 2, 2025. The award was issued on December 1, 2025, and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- AmerisourceBergen Drug Corp has been awarded a competitively competed delivery order by the Defense Logistics Agency (DLA) for Lantus SoloStar 100 Unit/ML insulin pens, valued at $1,294.28. The order, issued on November 12, 2025, with an ultimate completion date of November 13, 2025, represents a firm fixed price transaction with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will fulfill this delivery requirement from its corporate office location....
- The Defense Logistics Agency awarded a delivery order valued at $3,172.50 to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL insulin pens on September 9, 2025, with completion targeted for September 10, 2025. This competitive, non-set-aside award utilizes firm fixed pricing and represents a direct fulfillment of pharmaceutical supply needs for the Department of Defense. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a $1,350.99 delivery order to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL 3mL insulin pens, with an ultimate completion date of September 18, 2025. This firm fixed-price, non-set-aside contract was awarded competitively on September 17, 2025, with performance at AmerisourceBergen's Conshohocken, Pennsylvania headquarters. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $1,238.80 to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL 3mL insulin pens, with a completion date of June 30, 2025. This competitively awarded, non-set-aside contract employs firm fixed pricing and represents a pharmaceutical supply delivery to support federal medical procurement needs. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor...
- The Defense Logistics Agency awarded a $1,323.98 delivery order to AmerisourceBergen Drug Corp on December 1, 2025, for the supply of Lantus SoloStar 100 Unit/ml 3ml insulin pens. This competitively awarded, firm fixed-price contract with no set-aside designation is scheduled for completion by December 2, 2025, and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania facility. The award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA...
- The Defense Logistics Agency awarded a $4,157.91 delivery order to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/ml 3ml insulin pens, with an ultimate completion date of October 29, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The pharmaceutical distributor, headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,399.51 to AmerisourceBergen Drug Corp for the supply of Lantus SoloStar 100 Unit/ML 3ML insulin pens. This competitively awarded, non-set-aside contract features firm fixed pricing and is scheduled for completion by April 30, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery...
- SPE2DR25D3303Indefinite Delivery Contract
- SPE2DR25D3303-SPE2DR26F63G2Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,165.10 to AmerisourceBergen Drug Corp for Lantus Solostar 100 Unit/ml insulin pens (3ml). This non-set-aside, competitively awarded contract employs firm fixed pricing and is scheduled for completion by December 10, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor and a major pharmaceutical distributor supporting federal medical procurement, particularly for military and veteran healthcare systems. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical supply vehicle valued at $999,999,999.00 and extending through December 2026. The Lantus Solostar delivery supports the company's extensive portfolio of pharmaceutical products provided to the Defense Health Agency and other federal healthcare systems. AmerisourceBergen's federal contract awards demonstrate consistent capability to meet military medical supply requirements across therapeutic domains, ranging from specialty medications to diabetes treatments, vaccines, and medical devices. The firm fixed pricing structure and delivery order mechanism reflect the DLA's established approach to ensuring reliable pharmaceutical supply chains for military operations and healthcare facilities worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $12.2k | 12/8/25 |